In a major step toward curbing HIV transmission, Anambra State has become one of the first regions in Nigeria to introduce Lenacapavir, a long acting injectable drug designed to prevent HIV infection. The medication, administered just twice a year, is now available free of charge at select health facilities across the state, including the Chukwuemeka Odumegwu Ojukwu University Teaching Hospital. Public health officials say the rollout could mark a turning point in Nigeria’s fight against HIV, particularly for populations facing barriers to daily oral prevention methods. The introduction of Lenacapavir reflects a growing global shift toward long acting HIV prevention tools, which experts believe could improve adherence and reduce new infections. With Nigeria accounting for a significant portion of new HIV cases in West and Central Africa, the move is being closely watched by health advocates and policymakers alike.
What Happened
The Anambra State Government has officially launched the rollout of Lenacapavir, commercially known as LEN PrEP, a long acting injectable medication for HIV prevention. Unlike daily oral pre exposure prophylaxis, or PrEP, which requires consistent use, Lenacapavir is administered as a subcutaneous injection every six months. The drug is being provided at no cost to residents through designated health facilities, aiming to expand access to HIV prevention for high risk populations.
Why Public Health Officials Are Concerned
Nigeria remains one of the countries with the highest burden of HIV in the world, with an estimated 1.9 million people living with the virus. While oral PrEP has been available for years, adherence remains a persistent challenge, particularly among young people, sex workers, and men who have sex with men. Public health experts say that long acting prevention methods like Lenacapavir could help overcome barriers such as stigma, forgetfulness, and access to daily medication, which often hinder consistent use of oral PrEP.
The World Health Organization has endorsed long acting injectable PrEP as a critical tool in the global HIV response, noting that such innovations could accelerate progress toward the 2030 goal of ending AIDS as a public health threat. In Nigeria, where new HIV infections have plateaued in recent years, the introduction of Lenacapavir is seen as a potential game changer in prevention efforts.
Who May Be Affected
The rollout targets individuals at elevated risk of HIV infection, including adolescent girls and young women, sex workers, men who have sex with men, and people in serodiscordant relationships where one partner is living with HIV and the other is not. Health officials emphasize that the injection is not a replacement for condoms or other prevention methods but rather an additional option for those who may struggle with daily pill regimens.
Eligibility for Lenacapavir will be determined through counseling and screening at participating health facilities. The state government has urged residents to visit designated centers for assessment and to learn more about the drug’s benefits and potential side effects.
Government Response and Implementation
The Anambra State Ministry of Health, in collaboration with the National Agency for the Control of AIDS and international partners, has trained healthcare workers across selected facilities to administer the injection and provide pre and post counseling. The state has also launched community outreach programs to raise awareness about the new prevention option, particularly in rural and underserved areas.
A spokesperson for the state government stated that the rollout is part of a broader strategy to reduce new HIV infections by 50 percent by 2025. The initiative aligns with Nigeria’s National HIV/AIDS Strategic Framework, which prioritizes the expansion of prevention services and the integration of innovative tools into existing healthcare systems.
Prevention and Safety Guidance
Lenacapavir is approved for use as pre exposure prophylaxis in individuals who test negative for HIV and are at ongoing risk of infection. While the drug has shown high efficacy in clinical trials, health officials caution that it does not protect against other sexually transmitted infections or pregnancy. Users are advised to continue using condoms and other barrier methods for comprehensive protection.
Common side effects reported in trials include injection site reactions, such as pain, redness, or swelling, as well as mild headaches or fatigue. Serious adverse events are rare, but individuals are encouraged to report any unusual symptoms to their healthcare provider immediately.
What Readers Should Know
For residents of Anambra State, the introduction of Lenacapavir represents a significant advancement in HIV prevention. Those interested in the injection should visit designated health facilities for eligibility screening and counseling. It is important to note that while the drug is highly effective, it is not a cure for HIV and does not eliminate the need for regular testing and other prevention strategies.
Health advocates hope that the success of this rollout could pave the way for broader adoption of long acting PrEP across Nigeria, potentially transforming the landscape of HIV prevention in the country. For now, Anambra’s initiative stands as a model for how innovative tools can be integrated into public health programs to reach those most in need.
Key Takeaways
- Anambra State has launched Lenacapavir, a twice yearly injectable drug for HIV prevention, offered free at designated health facilities.
- The rollout targets high risk populations, including young women, sex workers, and men who have sex with men, who may face challenges with daily oral PrEP.
- Lenacapavir is not a replacement for condoms but an additional prevention option; users should continue regular HIV testing and other protective measures.
- The initiative aligns with Nigeria’s goal to reduce new HIV infections by 50 percent by 2025 and could serve as a model for other states.
Frequently Asked Questions
What is Lenacapavir, and how does it work?
Lenacapavir is a long acting injectable medication used for HIV prevention, known as pre exposure prophylaxis or PrEP. It works by blocking the virus from replicating in the body, providing protection for up to six months after a single injection. Unlike daily oral PrEP, which requires consistent pill taking, Lenacapavir offers a more convenient option for those at risk of HIV infection.
Who is eligible to receive the Lenacapavir injection in Anambra State?
The injection is available to individuals who test negative for HIV and are at ongoing risk of infection. This includes adolescent girls and young women, sex workers, men who have sex with men, and people in serodiscordant relationships. Eligibility is determined through counseling and screening at designated health facilities.
Is Lenacapavir safe, and what are the side effects?
Lenacapavir has been approved for use based on clinical trial data showing high efficacy and a favorable safety profile. Common side effects include mild injection site reactions, such as pain or swelling, as well as headaches or fatigue. Serious adverse events are rare, but users should report any unusual symptoms to their healthcare provider.
Does Lenacapavir protect against other sexually transmitted infections or pregnancy?
No, Lenacapavir only provides protection against HIV. It does not prevent other sexually transmitted infections or pregnancy. Health officials recommend continuing the use of condoms and other barrier methods for comprehensive protection.
Where can residents of Anambra State access the Lenacapavir injection?
The injection is available free of charge at designated health facilities across the state, including the Chukwuemeka Odumegwu Ojukwu University Teaching Hospital. Residents are advised to visit these centers for eligibility screening and counseling before receiving the injection.
Medical Review: MedSense Editorial Board
DISCUSSION (0)
POST A COMMENT